期刊
NATURE REVIEWS CLINICAL ONCOLOGY
卷 10, 期 7, 页码 372-374出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/nrclinonc.2013.86
关键词
-
类别
Tivantinib is being tested in a variety of phase II and phase III clinical trials as a highly selective, non ATP-competitive MET tyrosine kinase inhibitor. Its mechanism of action has been under scrutiny by two independent studies, which reveal that tivantinib is a cytotoxic drug acting on microtubule dynamics independently of MET. This finding has important implications for the interpretation of clinical results, for the design of new trials and for the selection of patients receiving tivantinib treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据